Highly purified CBD resolved two cases of life-threatening status epilepticus that resisted standard treatments

Both patients achieved resolution of status epilepticus after adding highly purified CBD (hpCBD) as add-on therapy via nasogastric tube, without adverse events. At 6-month follow-up, both patients continued on hpCBD treatment, which remained effective for seizure management.

Case series of two patients presenting with refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE). After standard antiseizure medications failed, hpCBD was administered via nasogastric tube as add-on therapy. Patients were followed for 6 months.

Refractory and super-refractory status epilepticus are medical emergencies with high mortality and very few effective treatments. While CBD is approved for specific epilepsy syndromes, this is among the first evidence of its potential in acute status epilepticus, a setting where new treatment options are desperately needed.

These cases expand the potential clinical applications of pharmaceutical-grade CBD beyond the chronic epilepsy syndromes for which it is already approved. The nasogastric delivery route is practical for ICU settings where patients cannot take oral medications. However, with only two cases, much more evidence is needed.

Only two cases, making it impossible to draw generalizable conclusions. Multiple other treatments were being given simultaneously, so the contribution of hpCBD alone is uncertain. No control group or comparison. Drug interactions with concurrent antiseizure medications were not fully characterized.